## Kieren J Mather

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/1771346/publications.pdf

Version: 2024-02-01

71102 40979 9,154 127 41 93 citations h-index g-index papers 132 132 132 12394 docs citations times ranked citing authors all docs

#	Article	IF	CITATIONS
1	Quantitative trait loci, G×E and G×G for glycemic traits: response to metformin and placebo in the Diabetes Prevention Program (DPP). Journal of Human Genetics, 2022, , .	2.3	O
2	The Impact of Physical Activity on the Prevention of Type 2 Diabetes: Evidence and Lessons Learned From the Diabetes Prevention Program, a Long-Standing Clinical Trial Incorporating Subjective and Objective Activity Measures. Diabetes Care, 2021, 44, 43-49.	8.6	41
3	The linearized disposition index augments understanding of treatment effects in diabetes. American Journal of Physiology - Endocrinology and Metabolism, 2021, 320, E169-E177.	3.5	2
4	OGTT Glucose Response Curves, Insulin Sensitivity, and $\hat{l}^2$ -Cell Function in RISE: Comparison Between Youth and Adults at Randomization and in Response to Interventions to Preserve $\hat{l}^2$ -Cell Function. Diabetes Care, 2021, 44, 817-825.	8.6	20
5	Cell-Free DNA Fragments as Biomarkers of Islet $\hat{l}^2$ -Cell Death in Obesity and Type 2 Diabetes. International Journal of Molecular Sciences, 2021, 22, 2151.	4.1	12
6	Cost-effectiveness of Community-Based Depression Interventions for Rural and Urban Adults With Type 2 Diabetes: Projections From Program ACTIVE (Adults Coming Together to Increase Vital Exercise) II. Diabetes Care, 2021, 44, 874-882.	8.6	5
7	Obstructive Sleep Apnea, Glucose Tolerance, and $\hat{I}^2$ -Cell Function in Adults With Prediabetes or Untreated Type 2 Diabetes in the Restoring Insulin Secretion (RISE) Study. Diabetes Care, 2021, 44, 993-1001.	8.6	16
8	Predictive utilities of lipid traits, lipoprotein subfractions and other risk factors for incident diabetes: a machine learning approach in the Diabetes Prevention Program. BMJ Open Diabetes Research and Care, 2021, 9, e001953.	2.8	7
9	Hepatic Fat in Participants With and Without Incident Diabetes in the Diabetes Prevention Program Outcome Study. Journal of Clinical Endocrinology and Metabolism, 2021, 106, e4746-e4765.	3.6	4
10	Influence of patient immigrant status on physician trainee diabetes treatment decisions: a virtual patient experimental study. Journal of Behavioral Medicine, 2021, 44, 662-672.	2.1	0
11	Precision and accuracy of hyperglycemic clamps in a multicenter study. American Journal of Physiology - Endocrinology and Metabolism, 2021, 320, E797-E807.	3.5	4
12	Association of glycemia with insulin sensitivity and $\hat{l}^2$ -cell function in adults with early type 2 diabetes on metformin alone. Journal of Diabetes and Its Complications, 2021, 35, 107912.	2.3	5
13	Hyperglucagonemia Does Not Explain the $\hat{I}^2$ -Cell Hyperresponsiveness and Insulin Resistance in Dysglycemic Youth Compared With Adults: Lessons From the RISE Study. Diabetes Care, 2021, 44, 1961-1969.	8.6	9
14	Baseline Predictors of Glycemic Worsening in Youth and Adults With Impaired Glucose Tolerance or Recently Diagnosed Type 2 Diabetes in the Restoring Insulin Secretion (RISE) Study. Diabetes Care, 2021, 44, 1938-1947.	8.6	16
15	Effect of Medical and Surgical Interventions on α-Cell Function in Dysglycemic Youth and Adults in the RISE Study. Diabetes Care, 2021, 44, 1948-1960.	8.6	2
16	Association of Glycemia, Lipids, and Blood Pressure With Cognitive Performance in People With Type 2 Diabetes in the Glycemia Reduction Approaches in Diabetes: A Comparative Effectiveness Study (GRADE). Diabetes Care, 2021, 44, 2286-2292.	8.6	4
17	Differential loss of $\hat{l}^2$ -cell function in youth vs. adults following treatment withdrawal in the Restoring Insulin Secretion (RISE) study. Diabetes Research and Clinical Practice, 2021, 178, 108948.	2.8	15
18	Shape of the OGTT glucose response curve: relationship with $\hat{l}^2$ -cell function and differences by sex, race, and BMI in adults with early type 2 diabetes treated with metformin. BMJ Open Diabetes Research and Care, 2021, 9, e002264.	2.8	12

#	Article	IF	CITATIONS
19	Islet Autoimmunity in Adults With Impaired Glucose Tolerance and Recently Diagnosed, Treatment Na $\tilde{A}$ -ve Type 2 Diabetes in the Restoring Insulin SEcretion (RISE) Study. Frontiers in Immunology, 2021, 12, 640251.	4.8	2
20	Withdrawal of medications leads to worsening of <scp>OGTT</scp> parameters in youth with impaired glucose tolerance or <scp>recentlyâ€diagnosed</scp> type 2 diabetes. Pediatric Diabetes, 2020, 21, 1437-1446.	2.9	7
21	Linearization of the Disposition Index equation allows evaluation of secretion-sensitivity coupling slopes. Journal of Diabetes and Its Complications, 2020, 34, 107589.	2.3	6
22	Circulating unmethylated CHTOP and INS DNA fragments provide evidence of possible islet cell death in youth with obesity and diabetes. Clinical Epigenetics, 2020, 12, 116.	4.1	17
23	Undiagnosed diabetes among immigrant and racial/ethnic minority adults in the United States: National Health and Nutrition Examination Survey 2011–2018. Annals of Epidemiology, 2020, 51, 14-19.	1.9	11
24	$\hat{l}^2\hat{a}$ €ells in youth with impaired glucose tolerance or early type 2 diabetes secrete more insulin and are more responsive than in adults. Pediatric Diabetes, 2020, 21, 1421-1429.	2.9	13
25	Salicylate administration suppresses the inflammatory response to nutrients and improves ovarian function in polycystic ovary syndrome. American Journal of Physiology - Endocrinology and Metabolism, 2020, 319, E744-E752.	3.5	5
26	Circulating sex hormone binding globulin levels are modified with intensive lifestyle intervention, but their changes did not independently predict diabetes risk in the Diabetes Prevention Program. BMJ Open Diabetes Research and Care, 2020, 8, e001841.	2.8	5
27	Prevalence of microvascular and macrovascular disease in the Glycemia Reduction Approaches in Diabetes - A Comparative Effectiveness (GRADE) Study cohort. Diabetes Research and Clinical Practice, 2020, 165, 108235.	2.8	20
28	Genetic ancestry markers and difference in A1c between African-American and White in the Diabetes Prevention Program. Journal of Clinical Endocrinology and Metabolism, 2019, 104, 328-336.	3.6	12
29	Benefits of Empagliflozin Beyond Enhancing Myocardial Energetics?. Journal of the American College of Cardiology, 2019, 74, 825-826.	2.8	1
30	Obesity and insulin sensitivity effects on cardiovascular risk factors: Comparisons of obese dysglycemic youth and adults. Pediatric Diabetes, 2019, 20, 849-860.	2.9	1
31	Does diabetes prevention translate into reduced long-term vascular complications of diabetes?. Diabetologia, 2019, 62, 1319-1328.	6.3	48
32	Recruitment effort and costs from a multi-center randomized controlled trial for treating depression in type 2 diabetes. Trials, 2019, 20, 621.	1.6	9
33	Metabolite Profiles of Incident Diabetes and Heterogeneity of Treatment Effect in the Diabetes Prevention Program. Diabetes, 2019, 68, 2337-2349.	0.6	22
34	Inhibition of Sodium Glucose Cotransporter-2 Mitigates Heart Failure Progression in Obesity. Journal of Cardiac Failure, 2019, 25, S30.	1.7	0
35	Association of Habitual Daily Physical Activity With Glucose Tolerance and Î <sup>2</sup> -Cell Function in Adults With Impaired Glucose Tolerance or Recently Diagnosed Type 2 Diabetes From the Restoring Insulin Secretion (RISE) Study. Diabetes Care, 2019, 42, 1521-1529.	8.6	9
36	Lack of Durable Improvements in $\hat{I}^2$ -Cell Function Following Withdrawal of Pharmacological Interventions in Adults With Impaired Glucose Tolerance or Recently Diagnosed Type 2 Diabetes. Diabetes Care, 2019, 42, 1742-1751.	8.6	56

#	Article	IF	Citations
37	Program ACTIVE II: Outcomes From a Randomized, Multistate Community-Based Depression Treatment for Rural and Urban Adults With Type 2 Diabetes. Diabetes Care, 2019, 42, 1185-1193.	8.6	32
38	Inhibition of sodium–glucose cotransporter-2 preserves cardiac function during regional myocardial ischemia independent of alterations in myocardial substrate utilization. Basic Research in Cardiology, 2019, 114, 25.	5.9	57
39	Association of Self-Reported Sleep and Circadian Measures With Glycemia in Adults With Prediabetes or Recently Diagnosed Untreated Type 2 Diabetes. Diabetes Care, 2019, 42, 1326-1332.	8.6	47
40	Analysis of serum Hsp90 as a potential biomarker of $\hat{I}^2$ cell autoimmunity in type 1 diabetes. PLoS ONE, 2019, 14, e0208456.	2.5	15
41	Non-traditional biomarkers and incident diabetes in the Diabetes Prevention Program: comparative effects of lifestyle and metformin interventions. Diabetologia, 2019, 62, 58-69.	6.3	25
42	Review of methods for measuring βâ€eell function: <scp>D</scp> esign considerations from the <scp>R</scp> estoring <scp>I</scp> nsulin <scp>S</scp> ecretion ( <scp>RISE</scp> ) < <scp>C</scp> onsortium. Diabetes, Obesity and Metabolism, 2018, 20, 14-24.	4.4	71
43	Depressive Symptoms, Antidepressant Medication Use, and Inflammatory Markers in the Diabetes Prevention Program. Psychosomatic Medicine, 2018, 80, 167-173.	2.0	8
44	Comparison of $\hat{I}^2$ -Cell Function Between Overweight/Obese Adults and Adolescents Across the Spectrum of Glycemia. Diabetes Care, 2018, 41, 318-325.	8.6	21
45	Evaluation of a Mixed Meal Test for Diagnosis and Characterization of PancrEaTogEniC DiabeTes Secondary to Pancreatic Cancer and Chronic Pancreatitis. Pancreas, 2018, 47, 1239-1243.	1.1	32
46	A Prospective Study to Establish a New-Onset Diabetes Cohort. Pancreas, 2018, 47, 1244-1248.	1.1	62
47	Impact of Gastric Banding Versus Metformin on Î <sup>2</sup> -Cell Function in Adults With Impaired Glucose Tolerance or Mild Type 2 Diabetes. Diabetes Care, 2018, 41, 2544-2551.	8.6	27
48	Combination GLP-1 and Insulin Treatment Fails to Alter Myocardial Fuel Selection vs. Insulin Alone in Type 2 Diabetes. Journal of Clinical Endocrinology and Metabolism, 2018, 103, 3456-3465.	3.6	5
49	Immune reconstitution in ART treated, but not untreated HIV infection, is associated with abnormal beta cell function. PLoS ONE, 2018, 13, e0197080.	2.5	10
50	Impact of Insulin and Metformin Versus Metformin Alone on $\hat{l}^2$ -Cell Function in Youth With Impaired Glucose Tolerance or Recently Diagnosed Type 2 Diabetes. Diabetes Care, 2018, 41, 1717-1725.	8.6	112
51	Metabolic Contrasts Between Youth and Adults With Impaired Glucose Tolerance or Recently Diagnosed Type 2 Diabetes: I. Observations Using the Hyperglycemic Clamp. Diabetes Care, 2018, 41, 1696-1706.	8.6	127
52	Episodic βâ€cell death and dedifferentiation during dietâ€induced obesity and dysglycemia in male mice. FASEB Journal, 2018, 32, 6150-6158.	0.5	26
53	Characteristics of Obstructive Sleep Apnea Across the Spectrum of Glucose Tolerance in Obese Adolescents. Frontiers in Endocrinology, 2018, 9, 281.	3.5	3
54	Inhibition of Sodium Glucose Cotransporterâ€⊋ Preserves Cardiac Function during Regional Myocardial Ischemia via a Frank‧tarling Mechanism. FASEB Journal, 2018, 32, .	0.5	0

#	Article	IF	Citations
55	Cardiovascular consequences of metabolic syndrome. Translational Research, 2017, 183, 57-70.	5.0	307
56	Effect of Long-Term Metformin and Lifestyle in the Diabetes Prevention Program and Its Outcome Study on Coronary Artery Calcium. Circulation, 2017, 136, 52-64.	1.6	97
57	Glucagon-Like Peptide 1 Receptor Activation Augments Cardiac Output and Improves Cardiac Efficiency in Obese Swine After Myocardial Infarction. Diabetes, 2017, 66, 2230-2240.	0.6	24
58	Retinopathy predicts progression of fasting plasma glucose: An Early Diabetes Intervention Program (EDIP) analysis. Journal of Diabetes and Its Complications, 2017, 31, 605-610.	2.3	4
59	Impact of Lifestyle and Metformin Interventions on the Risk of Progression to Diabetes and Regression to Normal Glucose Regulation in Overweight or Obese People With Impaired Glucose Regulation. Diabetes Care, 2017, 40, 1668-1677.	8.6	62
60	Statin use and risk of developing diabetes: results from the Diabetes Prevention Program. BMJ Open Diabetes Research and Care, 2017, 5, e000438.	2.8	97
61	Testosterone and depressive symptoms among men in the Diabetes Prevention Program. Psychoneuroendocrinology, 2016, 72, 63-71.	2.7	22
62	Obesity alters molecular and functional cardiac responses to ischemia/reperfusion and glucagon-like peptide-1 receptor agonism. Basic Research in Cardiology, 2016, 111, 43.	5.9	21
63	Imaging of myocardial fatty acid oxidation. Biochimica Et Biophysica Acta - Molecular and Cell Biology of Lipids, 2016, 1861, 1535-1543.	2.4	24
64	Lifestyle and Metformin Ameliorate Insulin Sensitivity Independently of the Genetic Burden of Established Insulin Resistance Variants in Diabetes Prevention Program Participants. Diabetes, 2016, 65, 520-526.	0.6	34
65	Change in adiponectin explains most of the change in HDL particles induced by lifestyle intervention but not metformin treatment in the Diabetes Prevention Program. Metabolism: Clinical and Experimental, 2016, 65, 764-775.	3.4	19
66	Response. Medicine and Science in Sports and Exercise, 2015, 47, 2001.	0.4	0
67	Failure of hyperglycemia and hyperinsulinemia to compensate for impaired metabolic response to an oral glucose load. Journal of Diabetes and Its Complications, 2015, 29, 238-244.	2.3	2
68	Elevations in Circulating Methylated and Unmethylated Preproinsulin DNA in New-Onset Type 1 Diabetes. Diabetes, 2015, 64, 3867-3872.	0.6	80
69	Antioxidant Vitamin C Prevents Decline in Endothelial Function during Sitting. Medical Science Monitor, 2015, 21, 1015-1021.	1.1	44
70	Treatment-Induced Changes in Plasma Adiponectin Do Not Reduce Urinary Albumin Excretion in the Diabetes Prevention Program Cohort. PLoS ONE, 2015, 10, e0136853.	2.5	1
71	Regression From Prediabetes to Normal Glucose Regulation Is Associated With Reduction in Cardiovascular Risk: Results From the Diabetes Prevention Program Outcomes Study. Diabetes Care, 2014, 37, 2622-2631.	8.6	97
72	[ <sup>13</sup> C]Glucose Breath Testing Provides a Noninvasive Measure of Insulin Resistance: Calibration Analyses Against Clamp Studies. Diabetes Technology and Therapeutics, 2014, 16, 102-112.	4.4	12

#	Article	IF	Citations
73	Lifestyle and Metformin Interventions Have a Durable Effect to Lower CRP and tPA Levels in the Diabetes Prevention Program Except in Those Who Develop Diabetes. Diabetes Care, 2014, 37, 2253-2260.	8.6	39
74	Profound defects in <i><b>β</b></i> >êcell function in screenâ€detected type 2 diabetes are not improved with glucoseâ€lowering treatment in the Early Diabetes Intervention Program (EDIP).  Diabetes/Metabolism Research and Reviews, 2014, 30, 767-776.	4.0	9
75	Clinical use of adiponectin as a marker of metabolic dysregulation. Best Practice and Research in Clinical Endocrinology and Metabolism, 2014, 28, 107-117.	4.7	43
76	Circulating natriuretic peptide concentrations reflect changes in insulin sensitivity over time in the Diabetes Prevention Program. Diabetologia, 2014, 57, 935-939.	6.3	16
77	$\hat{l}^2$ -Cell Failure in Type 2 Diabetes: Postulated Mechanisms and Prospects for Prevention and Treatment. Journal of Clinical Endocrinology and Metabolism, 2014, 99, 1983-1992.	3.6	171
78	Extrapancreatic effects of GLP-1 and other incretins. Reviews in Endocrine and Metabolic Disorders, 2014, 15, 169-169.	5.7	2
79	Glucagon-like peptide-1 (7–36) but not (9–36) augments cardiac output during myocardial ischemia via a Frank–Starling mechanism. Basic Research in Cardiology, 2014, 109, 426.	5.9	13
80	Cardiovascular and hemodynamic effects of glucagon-like peptide-1. Reviews in Endocrine and Metabolic Disorders, 2014, 15, 209-217.	5.7	12
81	The vascular endothelium in diabetes—a therapeutic target?. Reviews in Endocrine and Metabolic Disorders, 2013, 14, 87-99.	5.7	34
82	Impaired cardiometabolic responses to glucagon-like peptide 1 in obesity and type 2 diabetes mellitus. Basic Research in Cardiology, 2013, 108, 365.	5.9	42
83	Equivalence of arterial and venous blood for [11C]CO2-metabolite analysis following intravenous administration of 1-[11C]acetate and 1-[11C]palmitate. Nuclear Medicine and Biology, 2013, 40, 361-365.	0.6	12
84	Pentoxifylline, Inflammation, and Endothelial Function in HIV-Infected Persons: A Randomized, Placebo-Controlled Trial. PLoS ONE, 2013, 8, e60852.	2.5	23
85	Insulin resistance in the vasculature. Journal of Clinical Investigation, 2013, 123, 1003-1004.	8.2	94
86	Effects of Resistance Training on Adiposity and Metabolism after Spinal Cord Injury. Medicine and Science in Sports and Exercise, 2012, 44, 165-174.	0.4	146
87	Targeting the Consequences of the Metabolic Syndrome in the Diabetes Prevention Program. Arteriosclerosis, Thrombosis, and Vascular Biology, 2012, 32, 2077-2090.	2.4	49
88	The C Allele of <i>ATM</i> rs11212617 Does Not Associate With Metformin Response in the Diabetes Prevention Program. Diabetes Care, 2012, 35, 1864-1867.	8.6	65
89	Endogenous Sex Hormone Changes in Postmenopausal Women in the Diabetes Prevention Program. Journal of Clinical Endocrinology and Metabolism, 2012, 97, 2853-2861.	3.6	24
90	Racial/Ethnic Differences in Sex Hormone Levels among Postmenopausal Women in the Diabetes Prevention Program. Journal of Clinical Endocrinology and Metabolism, 2012, 97, 4051-4060.	3.6	34

#	Article	IF	CITATIONS
91	Intracoronary glucagon-like peptide 1 preferentially augments glucose uptake in ischemic myocardium independent of changes in coronary flow. Experimental Biology and Medicine, 2012, 237, 334-342.	2.4	15
92	Effect of regression from prediabetes to normal glucose regulation on long-term reduction in diabetes risk: results from the Diabetes Prevention Program Outcomes Study. Lancet, The, 2012, 379, 2243-2251.	13.7	384
93	Vitamin C prevents attenuation of flowâ€mediated dilation due to acutely altered SR patterns. FASEB Journal, 2012, 26, 853.26.	0.5	O
94	Cardiac responses to intravenous glucagonâ€like peptide 1 are impaired in metabolic syndrome. FASEB Journal, 2012, 26, .	0.5	0
95	Central adiposity associations to carbohydrate and lipid metabolism in individuals with complete motor spinal cord injury. Metabolism: Clinical and Experimental, 2011, 60, 843-851.	3.4	101
96	Contributions of dysglycaemia, obesity, and insulin resistance to impaired endotheliumâ€dependent vasodilation in humans. Diabetes/Metabolism Research and Reviews, 2011, 27, 354-361.	4.0	33
97	Mechanotransduction of shear in the endothelium: Basic studies and clinical implications. Vascular Medicine, 2011, 16, 365-377.	1.5	118
98	Influence of motor complete spinal cord injury on visceral and subcutaneous adipose tissue measured by multi-axial magnetic resonance imaging. Journal of Spinal Cord Medicine, 2011, 34, 99-109.	1.4	56
99	Role of Endogenous ETâ€1 in the Regulation of Myocardial Blood Flow in Lean and Obese Humans. Obesity, 2010, 18, 63-70.	3.0	14
100	Relationship of Body Composition, Metabolic Status, Antiretroviral Use, and HIV Disease Factors to Endothelial Dysfunction in HIV-Infected Subjects. AIDS Research and Human Retroviruses, 2010, 26, 847-854.	1.1	25
101	Simple modeling allows prediction of steady-state glucose disposal rate from early data in hyperinsulinemic glucose clamps. American Journal of Physiology - Endocrinology and Metabolism, 2010, 298, E229-E236.	3.5	10
102	Intra-Individual Variability of CO2 Breath Isotope Enrichment Compared to Blood Glucose in the Oral Glucose Tolerance Test. Diabetes Technology and Therapeutics, 2010, 12, 947-953.	4.4	9
103	Effect of Progression From Impaired Glucose Tolerance to Diabetes on Cardiovascular Risk Factors and Its Amelioration by Lifestyle and Metformin Intervention. Diabetes Care, 2009, 32, 726-732.	8.6	82
104	Adjusting Flow-Mediated Dilation for Shear Stress Stimulus Allows Demonstration of Endothelial Dysfunction in a Population with Moderate Cardiovascular Risk. Journal of Vascular Research, 2009, 46, 592-600.	1.4	66
105	Endothelin contributes differently to peripheral vascular tone and blood pressure in human obesity and diabetes. Journal of the American Society of Hypertension, 2008, 2, 182-191.	2.3	2
106	Adiponectin, Change in Adiponectin, and Progression to Diabetes in the Diabetes Prevention Program. Diabetes, 2008, 57, 980-986.	0.6	151
107	Relationship between brachial artery flow-mediated dilatation, hyperemic shear stress, and the metabolic syndrome. Vascular Medicine, 2008, 13, 263-270.	1.5	37
108	No Impairment of Endothelial Function or Insulin Sensitivity with 4 Weeks of the HIV Protease Inhibitors Atazanavir or Lopinavirâ€Ritonavir in Healthy Subjects without HIV Infection: A Placeboâ€Controlled Trial. Clinical Infectious Diseases, 2008, 47, 567-574.	5.8	62

#	Article	IF	Citations
109	Improvement in HIV-related endothelial dysfunction using the anti-inflammatory agent salsalate: a pilot study. Aids, 2008, 22, 653-655.	2.2	27
110	Endothelin Limits Insulin Action in Obese/Insulin-Resistant Humans. Diabetes, 2007, 56, 728-734.	0.6	108
111	Interactions of Endothelin and Insulin: Expanding Parameters of Insulin Resistance. Current Diabetes Reviews, 2006, 2, 317-327.	1.3	6
112	Insulin and Endothelin in the Acute Regulation of Adiponectin in Vivo in Humans. Obesity, 2005, 13, 582-588.	4.0	26
113	Interactions Between Endothelin and Nitric Oxide in the Regulation of Vascular Tone in Obesity and Diabetes. Diabetes, 2004, 53, 2060-2066.	0.6	144
114	Weight Loss and Endothelial Function in Obesity. Diabetes Care, 2003, 26, 1927-1928.	8.6	9
115	Diabetes and Heart Disease. Cardiology in Review, 2003, 11, 262-274.	1.4	28
116	Endothelin Contributes to Basal Vascular Tone and Endothelial Dysfunction in Human Obesity and Type 2 Diabetes. Diabetes, 2002, 51, 3517-3523.	0.6	201
117	Role of amylin in insulin secretion and action in humans: antagonist studies across the spectrum of insulin sensitivity. Diabetes/Metabolism Research and Reviews, 2002, 18, 118-126.	4.0	35
118	Improved endothelial function with metformin in type 2 diabetes mellitus. Journal of the American College of Cardiology, 2001, 37, 1344-1350.	2.8	481
119	Insulin Action in the Vasculature: Physiology and Pathophysiology. Journal of Vascular Research, 2001, 38, 415-422.	1.4	104
120	Prevalence of IgA-antiendomysial antibody in asymptomatic low bone mineral density. American Journal of Gastroenterology, 2001, 96, 120-125.	0.4	58
121	Cyclooxygenase-2 Blockade Does Not Impair Endothelial Vasodilator Function in Healthy Volunteers. Circulation, 2001, 104, 2879-2882.	1.6	72
122	Repeatability Characteristics of Simple Indices of Insulin Resistance: Implications for Research Applications. Journal of Clinical Endocrinology and Metabolism, 2001, 86, 5457-5464.	3.6	333
123	Tetrahydrobiopterin improves endothelial function in human saphenous veins. Journal of Thoracic and Cardiovascular Surgery, 2000, 120, 668-671.	0.8	46
124	Evidence for physiological coupling of insulin-mediated glucose metabolism and limb blood flow. American Journal of Physiology - Endocrinology and Metabolism, 2000, 279, E1264-E1270.	3.5	42
125	Preserved Forearm Endothelial Responses with Acute Exposure to Progesterone: A Randomized Cross-Over Trial of 17-β Estradiol, Progesterone, and 17-β Estradiol with Progesterone in Healthy Menopausal Women1. Journal of Clinical Endocrinology and Metabolism, 2000, 85, 4644-4649.	3.6	32
126	Quantitative Insulin Sensitivity Check Index: A Simple, Accurate Method for Assessing Insulin Sensitivity In Humans. Journal of Clinical Endocrinology and Metabolism, 2000, 85, 2402-2410.	3.6	3,201

#	Article	IF	CITATIONS
127	Hyperinsulinemia in polycystic ovary syndrome correlates with increased cardiovascular risk independent of obesity. Fertility and Sterility, 2000, 73, 150-156.	1.0	155